BIOHEART ANNOUNCES POSITIVE 6 MONTH DATA FROM ANGEL PHASE I TRIAL
Bioheart, Inc, biotechnology company focused on autologous cell therapy, released 6 month data from its phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). This phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell™) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months. All the patients demonstrated significant improvement in exercise capacity and echocardiogram testing beginning from 3 months since trial start.